Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.

Revenue projections:

Revenue projections for REGN
Revenue projections for REGN

REGN is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 4.126000
forwardPE 14.503335
debtToEquity 9.511000
earningsGrowth -0.026000
revenueGrowth 0.025000
grossMargins 0.445660
operatingMargins 0.231340
trailingEps 41.460000
forwardEps 52.741660

Regeneron Pharmaceuticals, Inc.'s current ratio 4.126, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, Regeneron Pharmaceuticals, Inc. can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
Regeneron Pharmaceuticals, Inc.'s Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
REGN's low growth in earnings and revenue indicates that profits could shrink. This signals potential financial difficulties for the company, suggesting that its profitability might be under pressure.
With positive gross and operating margins, REGN demonstrates its profitability and efficiency. These metrics show that the company is managing costs well while generating strong revenue, highlighting robust financial health.
Regeneron Pharmaceuticals, Inc.'s forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in Regeneron Pharmaceuticals, Inc.'s earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for REGN
Price projections for REGN

The gradual downward revision of REGN's price projections signals decreasing confidence in the company's future performance. Analysts are adjusting their expectations, reflecting uncertainty about REGN's growth potential.

Insider Transactions:

Insider Transactions for REGN
Insider Transactions for REGN


7 Regeneron Pharmaceuticals, Inc. shares were sold in recent transactions, with market price at 744.740007672991.There were no sell transactions during the period under consideration.More buys than sells have been occurring around the current price levels of REGN, potentially signaling investor optimism. This buying trend might be interpreted as a sign of a favorable outlook for the stock's future performance.

Recommendation changes over time:

Recommendations trend for REGN
Recommendations trend for REGN


Analysts have maintained a buy bias for REGN, which could prompt investors to consider the stock as a viable investment. With this positive outlook, REGN is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.